NSCLC patients - Globe Thesis

Keyword [NSCLC patients] Result: 21 - 40 \| Page: 2 of 7
21.	Characterization Of Cd14⁺HLA-DR^-/low MDSCs And Their Significance In NSCLC Patients
22.	Predictive Role Of Pretreatment EGFR T790M Mutation On TKI Therapy In NSCLC Patients-a Meta-analysis
23.	RNA Activation Reverses TKI Resistance In EGFR-mutant NSCLC Patients By Upregulating PTEN Expression
24.	Research Of ABCC3 And EHD1 On The Impact On The Efficacy Of Treatment In NSCLC Patients
25.	Study On The Expression Levels And Clinical Significance Of PD-1 And PD-L1 In Plasma And Tumor Tissues Of NSCLC Patients
26.	Detection EMl4-ALK Fusion Genes And Analysis Its Clinical Features In Nsclc Patients Possesing Clinical Characteristics Related To Egfr Mutations
27.	The Clinical Significance And Relationship Of Radiotherapy Of Plasma HIF-1αand VEGF-C MRNA In NSCLC Patients
28.	The Detection Method Of EGFR/KRAS Gene Mutations In Pleural Effusions Of NSCLC Patients And The Clinical Implication
29.	Study Of Survival Factors After Radiology And Clinical Ignificance Of Combined Targeting Therapy For NSCLC Patients With Brain Metastases
30.	The Blood Expression Level And Clinical Significance Of IGFs And IGF-bps In Advanced NSCLC Patients Resistant To EGFR-TKI Treatment
31.	Detection And The Clinical Value Of CD98in The Sera Of NSCLC Patients
32.	EGFR Genomic CA-simple Sequence Repeat Polymorphism In NSCLC Patients Treated With Tyrosine Kinase Inhibitor Therapy:a Meta-analysis And Systematic Review
33.	Analyses Of EGFR And K-ras Gene Mutations In NSCLC Patients With Initial Treatment
34.	Expression And Prognosis Of IL-17, MMP-9and Foxp3in Han Nationality And Uighur NSCLC Patients
35.	The Clinical Significance Of NSCLC Patients With Peripheral T Lymphocyte Subsets Expression After TKIs Treatment
36.	Circulating DNA EGFR Mutation And The Targeting Therapy Response In Advanced NSCLC Patients
37.	Relevant Research About Expression Level Of ERCC1and BRCA1in Prognosis Of NSCLC Patients Receiving Postoperative Adjuvant Chemotherapy
38.	Mutant-enriched PCR Combined With Pyrosequencing To Detect KRAS Mutations In Cancer Tissue And Matched Blood In NSCLC Patients
39.	Combination Regiment Of FuZhengKangAi Decotion And Erlotinib For Advanced NSCLC Patients
40.	Individualized Therapy For NSCLC Patients Based On Combined Detection Of Four Biomarkers
<<First <Prev Next> Last>> Jump to